When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRK was developing two candidates in this category - with Themis they were working on a measles-based one, and the IAVI a VSV-based one. But the company announced today that they're dropping both of them after looking at the first human Phase I data.
Adverse effects in the US, Israel, and Europe seem to me to be low and consistent with the clinical trial data.
We're still waiting on Novavax Phase II data; that's the most highly anticipated trial readout now behind the J&J one.